Activating the DDI2-NFE2L1-Proteasome System: A New Mechanism Protecting Against Ferroptosis

Study Background and Research Question

Ferroptosis is a regulated, non-apoptotic form of cell death characterized by iron-dependent lipid peroxidation and loss of plasma membrane integrity. While implicated in pathologies such as neurodegeneration and cancer, the molecular mechanisms governing cellular sensitivity or resistance to ferroptosis remain incompletely understood. Glutathione peroxidase 4 (GPX4) serves as a critical enzyme in mitigating ferroptosis by reducing lipid peroxides. Inhibition of GPX4 by compounds such as RSL3 leads to ferroptotic cell death, but emerging evidence suggests that protein homeostasis systems, particularly the ubiquitin-proteasome system (UPS), also play a protective role. The current study (Ofoghi et al., 2025) explores how the DDI2-NFE2L1-proteasome axis modulates cellular resilience to ferroptosis.

Key Innovation from the Reference Study

The central innovation of this research is the identification of a feedback loop, wherein the aspartyl protease DDI2 activates the transcription factor NFE2L1, which in turn upregulates proteasome subunit genes to restore proteasomal activity during ferroptosis. This adaptive mechanism is essential for cellular protection against ferroptosis triggered by GPX4 inhibition. The study also demonstrates that pharmacological inhibition of DDI2, including by the clinical HIV-1 protease inhibitor nelfinavir, sensitizes cells to ferroptosis (Ofoghi et al., 2025).

Methods and Experimental Design Insights

The authors employed an unbiased proteomic approach to chart ubiquitylation site changes in response to ferroptosis induction, using the GPX4 inhibitor RSL3. Proteasome activity was assessed via biochemical assays, and global ubiquitylation was monitored as a readout of UPS function. Genetic manipulation (knockout or knockdown) of DDI2 and NFE2L1 was performed to dissect the pathway’s role in ferroptosis sensitivity. Chemical inhibition studies included treatment with nelfinavir to explore potential off-target effects on DDI2 and subsequent impact on the proteasome and cell survival.

Protocol Parameters

• HIV protease inhibition assay | EC50: 31–43 nM (cell lines: CEM-SS, MT-2) | HIV infection research, cytotoxicity protection | Benchmarks nelfinavir’s potency for in vitro antiviral studies | product_spec
• Ferroptosis induction (RSL3) | 0.5–1 μM (typical range) | Lipid peroxidation/cell viability assays | Direct GPX4 inhibition to trigger ferroptosis; dose optimized for robust, reproducible effect | paper
• Proteasome activity assay | Adapted from manufacturer’s fluorogenic peptide substrate protocol | Proteasomal function assessment in ferroptosis context | Enables quantification of 26S proteasome activity post-treatment | workflow_recommendation
• Nelfinavir Mesylate treatment | 5–20 μM (inhibition of DDI2) | Sensitization to ferroptosis, UPS modulation | Based on observed DDI2 inhibition and increased ferroptosis susceptibility in cell models | paper

Core Findings and Why They Matter

The study establishes that RSL3-induced ferroptosis leads to reduced proteasome activity and widespread hyperubiquitylation, prompting an adaptive stress response. Activation of the transcription factor NFE2L1 is critical for restoring proteasome function, a process dependent on proteolytic cleavage by DDI2. Cells deficient in DDI2 fail to activate NFE2L1, resulting in impaired proteasome recovery and heightened ferroptosis sensitivity. Notably, pharmacological inhibition of DDI2 by nelfinavir further sensitized cells to ferroptotic death, linking a clinically approved HIV-1 protease inhibitor to the regulation of this cell death pathway (Ofoghi et al., 2025). These findings expand the conceptual landscape of ferroptosis regulation by integrating protein quality control and UPS remodeling into the cell’s response to lipid peroxidation stress. Therapeutically, the data suggest that DDI2 or NFE2L1 inhibition could potentiate ferroptosis-based strategies in cancer or other contexts where cell death induction is desired.

Comparison with Existing Internal Articles

Recent thought-leadership articles have begun to contextualize the dual utility of HIV-1 protease inhibitors, such as Nelfinavir Mesylate, across antiviral and cell death biology domains. For example, “Nelfinavir Mesylate: Leveraging HIV-1 Protease Inhibition in Antiviral and Ferroptosis Research” synthesizes evidence for Nelfinavir’s role both as an antiretroviral drug for HIV treatment and as a modulator of the ubiquitin-proteasome axis in ferroptosis models. Similarly, “Nelfinavir Mesylate: Bridging HIV Inhibition and Ferroptosis” provides protocol guidance for integrating Nelfinavir into research workflows that straddle virology and cell death signaling. However, the current reference paper goes further by mechanistically delineating how DDI2 and NFE2L1 constitute a feed-back loop essential for proteasome recovery during ferroptotic stress, and by directly demonstrating that nelfinavir’s DDI2-inhibitory activity is functionally relevant to ferroptosis sensitivity.

Limitations and Transferability

While the study offers compelling mechanistic insight, several limitations should be considered. First, much of the data derive from in vitro cell models, and the extent to which the DDI2-NFE2L1 axis modulates ferroptosis in vivo or across diverse tissue types requires further investigation. The use of nelfinavir as a DDI2 inhibitor in this context may not directly translate to clinical settings without additional pharmacodynamic and toxicity studies. Moreover, potential off-target effects of nelfinavir or other inhibitors should be systematically profiled. Finally, the focus on GPX4-dependent ferroptosis induction leaves open questions regarding other forms of regulated cell death and their interplay with the UPS.

Why this cross-domain matters, maturity, and limitations

Bridging the antiretroviral and cell death research domains enriches both fields—elucidating new mechanisms by which established HIV-1 protease inhibitors like nelfinavir can be repurposed to investigate or modulate ferroptosis. The reference study provides mechanistic proof-of-concept that HIV-1 protease inhibitors can serve as tools beyond virology, informing experimental design in oncology and protein homeostasis. However, the translational maturity of these findings remains preclinical; robust in vivo validation and safety assessments are needed before considering therapeutic applications (Ofoghi et al., 2025).

Research Support Resources

To facilitate experimental workflows exploring the interface of HIV protease inhibition and ferroptosis, researchers may utilize Nelfinavir Mesylate (SKU A3653), a potent and orally bioavailable HIV-1 protease inhibitor shown to modulate DDI2-NFE2L1 signaling. APExBIO supplies this compound with detailed characterization, supporting both traditional HIV infection research and emerging studies on proteasome regulation and ferroptosis. For protocol design and troubleshooting, see related articles in the APExBIO knowledge base and collaborative platforms (internal reference).